tbuckley/cabot-search huggingface dataset:
An Address Delivered at the Opening of the Section of Public Medicine
Authors: C. Cameron
Journal: BMJ (1884)

medicine are attached; and what is the consequence ?Those on the ob- stetric staff are driven to seek appointments to special hospitals for the treatment of diseases of women, to gain experience to enable them to teach ill their schools.We find Dr. Edis practising ovariotomy at the Chelsea Hospital for Women without a single death so far, and Dr. Win.Archdeckne Duncan removinig the whole uterus for cancer successfully at the Women's Hospital, Waterloc Bridge Road; and these are the men who are not permitted to do anything surgical at the Mid- dlesex Hospital, where they hold the appointments in the department of obstetrics and the diseases of women.This restriction makes their offices almost untenable, and, to say the least, excessively unpleasant.The special hospitals far surpass in abdominal surgery the great and ancient general hospitals of Lonidon, partly because the operations in connection therenwith are not permitted to be performed by those who make a special study of the subject, who have to teach it, and who are watching the growth and development of abdominal tumours from almost their commencement.The American and continental gynecologists who visit this country cannot understand it; they have no such arrangement.The consequence is, that they are attracted to the special hospitals, and not to our great general hospitals.And they find their way to our provincial hospitals, where this restraint is not placed upon the obstetric officers, and where, in consequence, we find these making a world-wide reputation for themselves.Take, for instance, Birmingham, Manchester, or Leeds.I trust the time will come, ere long, when our London hospitals, to which the medical schools are attached which have such restrictions, will see their error.At the present time, there is no common agree- ment amongst them.At four, at least, King's College, University College, St. George's, and Westminster, there is no rule against the obstetric physicians performing ovariotomy.At the first named, Dr. W. S. Playfair has practised a considerable number of these operations, and happily without a death; while at the others at all events an average success has been obtained by the obstetric physicians, West- minster Hospital excepted, where Dr. Potter, although having the right to operate, prefers to act in conjunction with one of the surgeons, who p)erforms the operation; and to this I can raise no objection so long as one has the option.What I ask is, that there shall be one nrule for all the general hospitals.What is right and proper at one hospital is surely so at another.There should be no difference in their arrange- ments.
Mental health matters
Authors: None The Lancet Global Health
Journal: The Lancet Global Health (2020)

October 10 marks World Mental Health Day. This year's campaign theme, developed by WHO, United for Global Mental Health, and the World Federation for Mental Health, recognises that investment in mental health has not matched rising global awareness of the scale of the problem in recent years. The campaign slogan—"Move for mental health: Let's invest"—calls the world to action and, for the first time, will be accompanied by a global online advocacy event.
Late stent malapposition following intracoronary radiation: A serial intravascular ultrasound study Hiroyuki Okura, Thosaphol Limpijankit, David P. Lee, Sydney Lo, Alan C. Yeung, Ron Waksman, Grzegorz L. Kaluza, Nadir M. Ali, Heidi N. Bonneau, Paul G. Yock, Albert E. Raizner, Gary S. Mintz, Peter J. Fitzgerald. Stanford University Medical Center, Stanford, CA, Baylor College of Medicine, Houston, TX
Journal: Journal of the American College of Cardiology (2001)
The Gene
Journal: JAMA (1998)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Ulk1-dependent alternative mitophagy plays a protective role during pressure overload in the heart
Authors: Jihoon Nah, Akihiro Shirakabe, Risa Mukai, Peiyong Zhai, Eun Ah Sung, Andreas Ivessa, Wataru Mizushima, Yasuki Nakada, Toshiro Saito, Chengchen Hu, Yong Keun Jung, Junichi Sadoshima
Journal: Cardiovascular Research (2022)

Well-controlled mitochondrial homeostasis, including a mitochondria-specific form of autophagy (hereafter referred to as mitophagy), is essential for maintaining cardiac function. The molecular mechanism mediating mitophagy during pressure overload (PO) is poorly understood. We have shown previously that mitophagy in the heart is mediated primarily by Atg5/Atg7-independent mechanisms, including Unc-51-like kinase 1 (Ulk1)-dependent alternative mitophagy, during myocardial ischaemia. Here, we investigated the role of alternative mitophagy in the heart during PO-induced hypertrophy.
Domestic Abstracts
Journal: JAMA (1989)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Hyperlipidemia potentiates in vitro angiogenesis with vascular endothelial growth factor Zhenguo Han, Damon Duquaine, Christina Addison, Sampath Parthasarathy, Jacques Nor, Sanjay Rajagopalan. University of Michigan, Department of Internal Medicine, Ann Arbor, MI, Emory University, Atlanta, GA
Journal: Journal of the American College of Cardiology (2001)
Précis of <i>Vigor: Neuroeconomics of Movement Control</i>
Authors: Reza Shadmehr, Alaa A Ahmed
Journal: Behavioral and Brain Sciences (2020)

Abstract Why do we run toward people we love, but only walk toward others? Why do people in New York seem to walk faster than other cities? Why do our eyes linger longer on things we value more? There is a link between how the brain assigns value to things, and how it controls our movements. This link is an ancient one, developed through shared neural circuits that on one hand teach us how to value things, and on the other hand control the vigor with which we move. As a result, when there is damage to systems that signal reward, like dopamine and serotonin, that damage not only affects our mood and patterns of decision-making, but how we move. In this book, we first ask why, in principle, evolution should have developed a shared system of control between valuation and vigor. We then focus on the neural basis of vigor, synthesizing results from experiments that have measured activity in various brain structures and neuromodulators, during tasks in which animals decide how patiently they should wait for reward, and how vigorously they should move to acquire it. Thus, the way we move unmasks one of our well-guarded secrets: how much we value the thing we are moving toward.
REVIVE study: A prospective observational study in chemotherapy (CTx) after nivolumab (NIVO) therapy for advanced gastric cancer (AGC).
Authors: Tomohiro Matsushima, Yukiya Narita, Toshihiro Misumi, Yasuhiro Sakamoto, Hiroshi Matsuoka, Hiroaki Tanioka, Takeshi Kawakami, Hiroto Miwa, Hirokazu Shoji, Atsushi Ishiguro, Takanobu Yamada, Sachio Fushida, Kou Miura, Katsunori Shinozaki, Takuro Mizukami, Tomohiro Nishina, Toshikazu Moriwaki, Seiichiro Mitani, Michio Nakamura, Kei Muro
Journal: Journal of Clinical Oncology (2022)

257 Background: NIVO therapy is a standard care treatment for heavily pretreated patients with AGC. Improvement in objective response rate (ORR) to CTx after NIVO therapy for various cancer types has been reported. However, the efficacy and safety of CTx for AGC after progression on NIVO remains unclear. Methods: The REVIVE trial was a prospective, multicenter, observational study that evaluated the efficacy and safety of CTx in NIVO-refractory or NIVO-intolerant patients (pts) with AGC (UMIN000032182). The primary endpoint was overall survival (OS) of CTx following NIVO therapy. The median threshold and expected survival times were set as 4.0 and 7.0 months (M). The secondary endpoints are ORR, disease control rate (DCR), progression-free survival (PFS), and incidence of adverse events (AEs), including immune-related adverse events (irAEs). CTx consisted of irinotecan alone (IRI), trifluridine/tipiracil alone (FT), and oxaliplatin-containing regimens (OX). Results: Of 395 pts treated with NIVO who met the eligibility at formal registration from Jun 2018 to Sep 2020, 199 pts who received CTx after NIVO were evaluated. Pt characteristics were as follows: median age, 69 years; male, 70%; ECOG PS 0/1/2, 38/51/12%; histology (diffuse/intestinal), 39/59%; metastatic lesions (peritoneum/liver/lung), 38/34/15%; number of metastatic organ sites (0–1/≥2), 40/60%; measurable lesions, 83%; and CTx regimens (IRI/FT/OX), 64/31/5%. Median OS and PFS were 7.5 M (95%CI, 6.7–9.7) at 145 events for OS and 2.9 M (95%CI, 2.2–3.5) at 184 events for PFS. The ORR and DCR were 17.0% (95%CI, 11.6–23.6) and 46.7% (95%CI, 38.9–54.6). Median OS, median PFS, ORR, and DCR according to CTx regimens (IRI/FT/OX) were 8.1/7.1/6.2 M, 3.3/2.8/2.4 M, 18.9/10.9/25.0%, and 47.8/43.5/50.0%, respectively. At the start of CTx, 42 pts had irAEs due to prior NIVO therapy. The most common any-grade and grade ≥3 AEs during CTx included decreased appetite (46% and 7.5%), fatigue (26% and 2.5%), nausea (24% and 1.5%), constipation (16% and 0%), and diarrhea (28% and 4.0%). No treatment-related deaths were observed. Conclusions: Prior NIVO therapy may lead to improved prognosis after CTx without unexpected AEs in pts with AGC, warranting further investigations after NIVO is approved as first-line treatment.[Table: see text]
Effects of aerobic exercise on fibroblast growth factor 21 in overweight and obesity. A systematic review
Authors: María Porflitt-Rodríguez, Valentina Guzmán-Arriagada, Romina Sandoval-Valderrama, Charmaine S. Tam, Francisca Pavicic, Pamela Ehrenfeld, Sergio Martínez-Huenchullán
Journal: Metabolism (2022)
Cytomegalovirus, Chlamydia pneumoniae, and helicobacter pylori IgG antibodies and restenosis poststent implantation. An angiographic and intravascular ultrasound study Francois Schiele, Marie-France Seronde, Mustafa Kemal Batur, Nicolas Meneveau, Pradip Sewoke, Agnes Bassignot, Gerard Couetdic, Fiona Caulfield, Jean-Pierre L. Bassand. University Hospital Jean-Minjoz, Besancon, France
Journal: Journal of the American College of Cardiology (2001)
TCT-294 Temporal Course of Vessel Healing after Everolimus-eluting Stent Implantation
Authors: Hiromasa Otake, Hirotoshi Hariki, Noritoshi Hiranuma, Ken-ichi Hirata, Takumi Inoue, Masamichi Iwasaki, Hiroto Kinutani, Akihide Konishi, Masayuki Nakagawa, Toshiro Shinke, Junya Shite, Yu Taniguchi
Journal: Journal of the American College of Cardiology (2012)
Higher early mortality among younger African Americans after myocardial infarction: Analysis of the national registry of myocardial infarction-2 Ajay Manhapra, John G. Canto, Viola Vaccarino, Lori Parsons, Hal V. Barron, Nathan R. Every, Catarina A. Kiefe, William J. Rogers, W Douglas Weaver, Steven Borzak. Henry Ford Heart and Vascular Institute, Detroit, MI, University of Alabama at Birmingham Medical Center, Birmingham, AL
Journal: Journal of the American College of Cardiology (2001)
Ectopic Pregnancy—United States, 1990-1992
Journal: JAMA (1995)

Ectopic pregnancy is the leading cause of pregnancy-related death during the first trimester (1). Women who have one ectopic pregnancy are at increased risk for another such pregnancy and for future infertility (2). In the United States, the reported number of hospitalizations for ectopic pregnancy increased from 17,800 in 1970 to 88,400 in 1989 (1). This report summarizes trends in hospitalizations for ectopic pregnancy in the United States during 1990-1992 and presents the incidence of ectopic pregnancy in 1992, based on aggregated inpatient and outpatient data.
Adherence with the multitarget stool DNA test for colorectal cancer screening in rural southeastern Kentucky.
Authors: Forrest Smith, Joseph Elsoueidi, Lauren Wisnieski, Sandhya Kolagatla, Nagabhishek Moka
Journal: Journal of Clinical Oncology (2022)

64 Background: Colorectal cancer (CRC) screening has shown to improve early detection and reduce mortality. Despite, the availability of multiple screening tests for CRC, the current screening rates remains below the national goal. The multi-target stool (MTS) DNA test (commercially known as Cologuard) has contributed to an increase in population adherence to CRC screening and is currently recommended by multiple guidelines. Southeastern Kentucky (SE KY) has a high incidence of colorectal cancer and a low rate of CRC screening. The aim of this study is to assess the adherence to the MTSDNA test in rural SE KY. Methods: A retrospective review of all patients 45 and older with a MTSDNA test ordered between August 2020 and February 2021 at a large primary care group in SE KY. All patients had Tests ordered and kits delivered. Cross-sectional adherence was defined as completion and return of the kit within 180 days from test order and was assessed as overall adherence and by patient characteristics including age, sex and healthcare coverage. Results: 450 tests were ordered. 160 (35%) were male and 290 (65%) females. Mean age was 62 with age range (46-87). 207 tests were returned with a cross-sectional adherence of 46%. Adherence was significantly lower for age 45 - 55 at 35.2% (26.2-45.2) compared to age 55 - 65 at 48.9% (40.9-56.3), 65 and older at 50.0% (42.3-57.7) (P = 0.04). Highest adherence with Medicaid coverage 65.4% [44.3-82.8] and lowest in Managed Care Organization (MCO) coverage 34.0% [4.7-44.2] (P &lt; 0.01). Gender was not associated with adherence (P = 0.75). Conclusions: This retrospective study showed that only 46% of patients were adherent to the MTS DNA test for colorectal screening which is significantly lower than previously reported in larger studies and further studies are needed to identify the barriers to non-adherence to this test, especially in the younger population with alarming increase in incidence of CRC. There is impending need to implement different strategies to improve screening adherence.
JAMA Dermatology
Journal: JAMA Dermatology (2022)

Mission Statement JAMA Dermatology publishes information concerning the skin, its diseases, and their treatment.Its mission is to explicate the structure and function of the skin and its diseases and the art of using this information to deliver optimal medical and surgical care to the patient.We attempt to enhance the understanding of cutaneous pathophysiology and improve the clinician's ability to diagnose and treat skin disorders.This journal has a particular interest in publishing clinical and laboratory studies that reveal new information pertinent to the interests and needs of the medical dermatologist, dermatologic surgeon, and all those concerned with state-of-the-art care of cutaneous disease.We believe that knowledge derived from well-designed clinical trials and studies of cost-eff ectiveness are especially important for improving the practice of dermatology.Studies that increase the understanding of the outcome of treatment or the means by which the burden of dermatologic disease can be measured and reduced to promote the health of patients with skin disease will receive special priority.The journal regularly publishes reports on clinical investigations, editorials, and reviews.It also features reports and discussions on clinicopathologic correlations; clinical disorders of unique didactic value; pharmacologic, medical and surgical therapeutics; and ethical, moral, socioeconomic, and political issues.
Galectin-3 inhibits cardiac contractility via a tumor necrosis factor alpha-dependent mechanism in cirrhotic rats
Authors: Ki Tae Yoon, Hongqun Liu, Jing Zhang, Sojung Han, Samuel S. Lee
Journal: Clinical and Molecular Hepatology (2022)

Galectin-3 plays a key pathogenic role in cardiac hypertrophy and heart failure. The present study aimed to investigate the effects of galectin-3 on cardiomyopathy - related factors and cardiac contractility in a rat model of cirrhotic cardiomyopathy.Rats were divided into two sets, one for a functional study, the other for cardiac contractile-related protein evaluation. There were four groups in each set: sham operated and sham plus N-acetyllactosamine (N-Lac, a galectin-3 inhibitor; 5 mg/kg); bile duct ligated (BDL) and BDL plus N-Lac. Four weeks after surgery, ventricular level of galectin-3, collagen I and III ratio, tumor necrosis factor alpha (TNFα), and brain natriuretic peptide (BNP) were measured either by Western blots or immunohistochemistry or enzyme-linked immunosorbent assay. Blood pressure was measured by polygraph recorder. Cardiomyocyte contractility was measured by inverted microscopy.Galectin-3 and collagen I/III ratio were significantly increased in cirrhotic hearts. TNFα and BNP were significantly increased in BDL serum and heart compared with sham controls. Galectin-3 inhibitor significantly decreased galectin-3, TNFα, and BNP in cirrhotic hearts but not in sham controls. N-Lac also significantly improved the blood pressure, and systolic and diastolic cardiomyocyte contractility in cirrhotic rats but had no effect on sham controls.Increased galectin-3 in the cirrhotic heart significantly inhibited contractility via TNFα. Inhibition of galectin-3 decreased the cardiac content of TNFα and BNP and reversed the decreased blood pressure and depressed contractility in the cirrhotic heart. Galectin-3 appears to play a pathogenic role in cirrhotic cardiomyopathy.
Queries and Minor Notes
Journal: JAMA (1933)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
IDH-mutated gliomas promote epileptogenesis through <scp>d</scp>-2-hydroxyglutarate-dependent mTOR hyperactivation
Authors: Armin Mortazavi, Islam Fayed, Muzna Bachani, Tyrone Dowdy, Jahandar Jahanipour, Anas Khan, Jemima Owotade, Stuart Walbridge, Sara K Inati, Joseph Steiner, Jing Wu, Mark Gilbert, Chun Zhang Yang, Mioara Larion, Dragan Maric, Alexander Ksendzovsky, Kareem A Zaghloul
Journal: Neuro-Oncology (2022)

Abstract Background Uncontrolled seizures in patients with gliomas have a significant impact on quality of life and morbidity, yet the mechanisms through which these tumors cause seizures remain unknown. Here, we hypothesize that the active metabolite d-2-hydroxyglutarate (d-2-HG) produced by the IDH-mutant enzyme leads to metabolic disruptions in surrounding cortical neurons that consequently promote seizures. Methods We use a complementary study of in vitro neuron-glial cultures and electrographically sorted human cortical tissue from patients with IDH-mutant gliomas to test this hypothesis. We utilize micro-electrode arrays for in vitro electrophysiological studies in combination with pharmacological manipulations and biochemical studies to better elucidate the impact of d-2-HG on cortical metabolism and neuronal spiking activity. Results We demonstrate that d-2-HG leads to increased neuronal spiking activity and promotes a distinct metabolic profile in surrounding neurons, evidenced by distinct metabolomic shifts and increased LDHA expression, as well as upregulation of mTOR signaling. The increases in neuronal activity are induced by mTOR activation and reversed with mTOR inhibition. Conclusion Together, our data suggest that metabolic disruptions in the surrounding cortex due to d-2-HG may be a driving event for epileptogenesis in patients with IDH-mutant gliomas.
Research brief
Authors: Jane Bradbury
Journal: The Lancet Infectious Diseases (2014)

The A/H7N9 avian influenza strain that emerged in China in 2013 could initiate a lethal influenza pandemic if it acquires the ability to spread between people. Researchers now report that a vaccine produced by cell culture from a synthetic A/H7N9 seed virus is immunogenic in adults. In a phase 1 study of 402 healthy adults, vaccine formulations with and without adjuvant were well tolerated and induced effective immune responses in individuals without pre-existing immunity to the strain. These findings bring the development of a vaccine that could be rapidly produced in the event of an A/H7N9 pandemic a step closer.